Ludovic Evesque

Publications by Year

Research Areas

Gastric Cancer Management and Outcomes, Colorectal and Anal Carcinomas, Colorectal Cancer Treatments and Studies, Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics

Most-Cited Works

• → Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300(2018)502 cited
• → Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer(2022)295 cited
• → Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial(2024)211 cited
• → Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study(2024)207 cited
• → A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization(2010)179 cited
• → Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial(2024)153 cited
• → Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.(2023)105 cited
• → Planned organ preservation for early T2-3 rectal adenocarcinoma: A French, multicentre study(2018)85 cited
• → Effect of Detoxification on Liver Stiffness Assessed by Fibroscan® in Alcoholic Patients(2010)76 cited
• → Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens(2019)72 cited